Thank you very much, Mr. Chair.
I am just going to continue in a similar vein to Monsieur Ste-Marie, who I think was asking about the capital requirements of scaling up. Often the model in Canada seems to be that companies will develop a product to the point where it's ready for a wider commercialization and then sell to a firm—a U.S. firm or a firm from somewhere else—that then takes that work on.
He was asking if it makes sense to have patient capital—which is a rough translation of the French; maybe that's the term in English as well—and about what could be done to put that in place so that when products are ready for scale up, a better financing infrastructure is already available and in place.
I wonder if you want to speak to that or if you think that's not really the main issue and that it is some of the other factors you were discussing before.